Primrose Syndrome

1. Disease Information

1.1 Concise overview

Primrose syndrome is a rare, typically de novo autosomal dominant multisystem disorder characterized by neurodevelopmental impairment (developmental delay, intellectual disability, behavioral abnormalities including autism), postnatal macrocephaly, characteristic facial features, and a progressive component with calcification/ossification of the external ears, distal muscle wasting, contractures, skeletal abnormalities, and metabolic/endocrine disturbances (including altered glucose metabolism/diabetes and thyroid dysfunction). (melis2020primrosesyndromecharacterization pages 2-4, arora2021primrosesyndrome pages 1-3, melis2020primrosesyndromecharacterization pages 1-2)

1.2 Key identifiers (with notes on availability)

• OMIM disease: 259050 (Primrose syndrome) (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)
• Causal gene OMIM: 606025 (ZBTB20) (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)
• MONDO: MONDO_0009798 (Primrose syndrome) (OpenTargets Search: Primrose syndrome-ZBTB20)
• Orphanet cross-mapped entity/name used in resources: Orphanet_3042 (“Intellectual disability - cataracts - calcified pinnae - myopathy”) (OpenTargets Search: Primrose syndrome-ZBTB20)
• ICD / MeSH: not explicitly provided in the retrieved excerpts; would require direct consultation of ICD/MeSH registries (not available in current tool outputs).

1.3 Synonyms / alternative names

A commonly used resource synonym is “Intellectual disability - cataracts - calcified pinnae - myopathy” (Orphanet_3042), reflecting the characteristic clinical tetrad in some individuals. (OpenTargets Search: Primrose syndrome-ZBTB20)

1.4 Evidence provenance

Most knowledge is derived from aggregated disease-level resources and cohorts (notably a 42-patient series), plus individual case reports—including multiple 2023–2024 publications that expand early-life phenotypes and management experience. (melis2020primrosesyndromecharacterization pages 2-4, li2024noveldenovo pages 1-2, tugci2024cochlearimplantationin pages 2-4)

2. Etiology

2.1 Primary causal factor

Primrose syndrome is caused by heterozygous pathogenic (or likely pathogenic) variants in ZBTB20, encoding a BTB–zinc finger transcriptional repressor. (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)

2.2 Risk factors

• Genetic: presence of a pathogenic ZBTB20 variant; most reported cases are de novo. (arora2021primrosesyndrome pages 10-13, long2023aninfantwith pages 1-2)
• Non-genetic/environmental: no established environmental risk factors were identified in the retrieved literature excerpts.

2.3 Protective factors / gene–environment interactions

No protective factors or gene–environment interactions specific to Primrose syndrome were identified in the retrieved evidence.

3. Phenotypes

3.1 Key phenotypic spectrum and frequencies (cohort-based)

The largest consolidated cohort evidence in the retrieved texts is the 42-patient phenotype series, which provides frequencies for multiple core findings. Examples include: - Macrocephaly: 29/38 (76%) (melis2020primrosesyndromecharacterization pages 2-4) - Moderate–severe intellectual disability: 33/39 (85%) (melis2020primrosesyndromecharacterization pages 2-4) - Autism: 20/33 (61%) (melis2020primrosesyndromecharacterization pages 2-4) - Hypotonia: 26/34 (76%) (melis2020primrosesyndromecharacterization pages 2-4) - External ear calcification: 14/28 (50%) overall, but 12/12 adults (100%) where assessed (melis2020primrosesyndromecharacterization pages 2-4)

Phenotypes with strong age-dependence (often emerging in adolescence) include ear calcification, cystic bone lesions, muscle wasting, and contractures. (melis2020primrosesyndromecharacterization pages 1-2)

3.2 Age of onset, progression, and severity

A consistent theme across cohort and review sources is progressive somatic involvement: - Cardinal features such as calcification of the external ears, cystic bone lesions, muscle wasting, and contractures “typically develop between 10 and 16 years of age.” (melis2020primrosesyndromecharacterization pages 1-2) - Muscle wasting may first be noticed around 11 years, and contractures around 10 years, with progression over time. (melis2020primrosesyndromecharacterization pages 4-7)

3.3 Quality of life / functional impact (inferred from clinical course)

Functional impairment can become substantial due to musculoskeletal progression; GeneReviews-style content notes walking difficulty and eventual wheelchair dependence in some individuals due to distal wasting and contractures. (arora2021primrosesyndromea pages 6-8)

3.4 Suggested HPO terms

A phenotype-to-HPO mapping (including onset and frequency where available) is provided in Artifact 01.

Table: This table maps major Primrose syndrome manifestations to suggested HPO terms with onset/progression notes and frequency data where available, mainly from the 42-patient cohort and GeneReviews-style summary. It is useful for disease knowledge base curation and phenotype annotation.

4. Genetic / Molecular Information

4.1 Causal gene

• ZBTB20 (BTB-ZF transcriptional repressor). (arora2021primrosesyndrome pages 10-13, stellacci2018clinicalandfunctional pages 13-16)

4.2 Pathogenic variants (classes and location)

Across case reports and cohort summaries, most disease-causing ZBTB20 variants are reported as de novo and frequently missense variants in C-terminal C2H2 zinc-finger motifs, consistent with disruption of DNA binding and/or dominant-negative behavior. (sogukpınar2024anovelzbtb20 pages 1-2, juven2020primrosesyndromea pages 1-2)

Recent variant examples (2023–2024): - c.1916G>A (p.Cys639Tyr) (de novo) in a 2024 behavioral-treatment case. (moon2024resolutionofsevere pages 1-2) - c.1948A>C (p.Asn650His) (de novo) in an early-childhood presentation. (sogukpınar2024anovelzbtb20 pages 1-2) - c.1927T>A (p.Phe643Ile) (de novo), classified ACMG “likely pathogenic” with PS2 + PM2_supporting + PP3 + PP4. (li2024noveldenovo pages 5-7) - A reported frameshift/truncating variant c.1038dup (p.Ile347AspfsTer23) identified by fetal exome sequencing in a prenatal diagnosis report, illustrating that non-missense loss-of-function alleles can also occur in published cases (though classic Primrose syndrome is enriched for missense ZnF variants). (long2023aninfantwith pages 1-2)

4.3 Variant mechanism (dominant-negative vs haploinsufficiency)

Multiple sources suggest that a dominant-negative mechanism is plausible/likely for many missense zinc-finger variants: - A GeneReviews-style summary explicitly states: “A dominant-negative mechanism has been proposed.” (arora2021primrosesyndrome pages 10-13) - Functional work showed mutant ZBTB20 proteins localize to the nucleus but are not stably chromatin bound and reduce DNA binding even when co-expressed with wild-type, supporting interference with normal function. (stellacci2018clinicalandfunctional pages 13-16) - Genotype–phenotype comparisons report that missense SNVs are associated with more progressive multisystem involvement (hearing loss, ectopic calcifications, muscle wasting/contractures) than 3q13.31 deletions/truncating variants, consistent with stronger dominant-negative effects for some missense alleles. (juven2020primrosesyndromea pages 1-2)

4.4 Epigenetics, chromosomal abnormalities, modifier genes

• Chromosomal abnormality context: 3q13.31 microdeletions that include ZBTB20 can produce overlapping phenotypes and are used in differential diagnosis comparisons. (juven2020primrosesyndromea pages 1-2, long2023aninfantwith pages 6-7)
• No Primrose syndrome–specific modifier genes or epigenetic disease drivers were identified in the retrieved evidence.

5. Environmental Information

No disease-specific environmental, lifestyle, or infectious triggers were identified in the retrieved evidence; Primrose syndrome is primarily genetic in etiology. (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)

6. Mechanism / Pathophysiology

6.1 Molecular function and upstream lesion

ZBTB20 is a BTB-ZF transcriptional repressor with an N-terminal BTB domain (protein–protein interactions) and C-terminal C2H2 zinc fingers (DNA binding). (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)

6.2 AFP dysregulation (liver transcriptional repression)

A proposed mechanism for a characteristic biomarker is that ZBTB20 normally represses AFP expression in liver; ZBTB20 dysfunction “leads to the unblocking of AFP synthesis in the liver (normally, the gene acts as a repressor)” leading to elevated serum AFP in Primrose syndrome. (głowskaciemny2023roleofalphafetoprotein pages 3-4, głowskaciemny2023roleofalphafetoprotein pages 4-6)

6.3 Neurodevelopmental mechanisms

Neurodevelopmental disorder mechanisms are supported by animal and cellular neurobiology work: - ZBTB20 perturbation affects hippocampal development and CA1 pyramidal neuron maturation; RNAi downregulation in mouse hippocampus reduces apical dendritic arborization, and genetic models show hippocampal circuit defects. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2) - Cultured neuron experiments show ZBTB20 variants can alter dendritic spine morphology and dendritic arborization/length, providing a plausible substrate for cognition/behavior phenotypes. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)

6.4 Metabolic mechanisms

Clinical biochemical patterns and mechanistic studies link ZBTB20 to metabolic homeostasis: - Clinically, “unexplained anemia, disturbed glucose metabolism, and increased AFP levels are cardinal features of PS,” and metabolic investigations suggest disturbed mitochondrial fatty-acid oxidation with abnormal acylcarnitines and urine organic acids in a subset. (melis2020primrosesyndromecharacterization pages 8-10, melis2020primrosesyndromecharacterization pages 4-7) - Functional and review evidence links ZBTB20 to regulation of metabolic genes and β-cell function relevant to glucose homeostasis. (stellacci2018clinicalandfunctional pages 13-16)

6.5 Dominant-negative functional evidence

Functional assays in a Primrose-syndrome–relevant context found that ZnF-region substitutions can disrupt DNA contacts (loss of a DNA-backbone hydrogen bond) and reduce chromatin binding/DNA binding to an AFP promoter oligo, consistent with a transcriptional dysregulation mechanism and dominant-negative interference with wild-type protein. (stellacci2018clinicalandfunctional pages 13-16)

6.6 Suggested ontology terms

• GO biological processes (suggested): regulation of transcription by RNA polymerase II; neurogenesis; regulation of neuron differentiation; regulation of glucose metabolic process; lipid metabolic process.
• CL cell types (suggested): cortical pyramidal neuron; hippocampal CA1 pyramidal neuron; astrocyte; pancreatic beta cell; hepatocyte.

(These ontology suggestions are aligned with functional roles reported in mechanistic evidence but are not explicitly enumerated in the retrieved excerpts.) (stellacci2018clinicalandfunctional pages 13-16, jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)

7. Anatomical Structures Affected

7.1 Organ systems (high-confidence)

• Central nervous system: neurodevelopmental impairment, corpus callosum anomalies, seizures in a subset. (melis2020primrosesyndromecharacterization pages 2-4, long2023aninfantwith pages 1-2)
• Auditory system: sensorineural hearing loss; cochlear implantation has been performed in at least one reported patient. (tugci2024cochlearimplantationin pages 2-4)
• Musculoskeletal system: distal muscle wasting, contractures, skeletal abnormalities; potential wheelchair dependence. (arora2021primrosesyndromea pages 6-8, melis2020primrosesyndromecharacterization pages 4-7)
• Endocrine/metabolic: disturbed glucose metabolism/diabetes; hypothyroidism in some cases. (melis2020primrosesyndromecharacterization pages 8-10, arora2021primrosesyndromea pages 6-8)
• Liver (biomarker biology): AFP dysregulation plausibly arises from hepatic transcriptional derepression. (głowskaciemny2023roleofalphafetoprotein pages 3-4)

7.2 Suggested UBERON terms (examples)

• Hippocampus, cerebral cortex, corpus callosum, cochlea/inner ear, skeletal muscle, testis, liver, pancreas.

8. Temporal Development

• Early/childhood: macrocephaly, developmental delay, hypotonia, facial gestalt, early hearing loss. (melis2020primrosesyndromecharacterization pages 2-4, arora2021primrosesyndromea pages 6-8)
• Puberty/adolescence: hallmark progression—ear calcification, cystic bone lesions, muscle wasting, contractures—often emerges 10–16 years. (melis2020primrosesyndromecharacterization pages 1-2)
• Adulthood: cataracts, diabetes, sparse body hair, testicular tumor risk may become relevant; recognition is often easier in adults. (melis2020primrosesyndromecharacterization pages 8-10, melis2020primrosesyndromecharacterization pages 10-11)

9. Inheritance and Population

9.1 Inheritance

Primrose syndrome is autosomal dominant, and most reported probands are de novo. (arora2021primrosesyndrome pages 10-13, long2023aninfantwith pages 1-2)

9.2 Recurrence risk / mosaicism

If the pathogenic variant is present in an affected parent, recurrence risk to sibs is 50%; if parental leukocyte testing is negative, sib recurrence risk is estimated ~1% due to possible germline mosaicism. (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)

9.3 Epidemiology

Robust incidence/prevalence data are not available from the extracted primary cohort excerpts; one review-style AFP paper cites a rough prevalence of ~1:1,000,000 births. (głowskaciemny2023roleofalphafetoprotein pages 3-4)

10. Diagnostics

10.1 Clinical recognition and key supportive findings

Clinical suspicion is raised by the combination of neurodevelopmental impairment, macrocephaly/overgrowth, hearing loss, progressive ear calcification and muscle wasting/contractures, and supportive biochemical features (AFP elevation, anemia, glucose dysregulation, occasional metabolic profiling abnormalities). (melis2020primrosesyndromecharacterization pages 2-4, melis2020primrosesyndromecharacterization pages 8-10)

10.2 Genetic testing strategy (recommended approaches)

A GeneReviews-style diagnostic workflow includes: - Single-gene testing of ZBTB20 (sequence analysis), followed by deletion/duplication analysis if negative. - Alternatively, multigene panels for intellectual disability that include ZBTB20, or exome/genome sequencing when the phenotype is nonspecific. - ACMG/AMP interpretation: pathogenic/likely pathogenic variants are diagnostic; VUS does not establish/exclude diagnosis. (arora2021primrosesyndrome pages 1-3)

Recent real-world implementations include trio whole-exome sequencing with Sanger confirmation and CNV testing (CNV-seq). (li2024noveldenovo pages 5-7)

10.3 Differential diagnosis

Differentials explicitly mentioned include 3q13.31 microdeletion syndrome (including ZBTB20), Fragile X syndrome, and DiGeorge syndrome, reflecting overlapping neurodevelopmental phenotypes. (long2023aninfantwith pages 6-7)

11. Outcome / Prognosis

11.1 Overall course

Primrose syndrome is progressive for many somatic features (muscle wasting, contractures, calcifications), but available cohort evidence suggests no clear progressive cognitive decline: cognition “does not seem to decline with age,” though detailed longitudinal testing is limited. (melis2020primrosesyndromecharacterization pages 8-10)

11.2 Longevity / life expectancy

Longitudinal outcome data are limited; the oldest reported individual is 53 years in GeneReviews-style and case report summaries. (arora2021primrosesyndromea pages 6-8, long2023aninfantwith pages 6-7)

11.3 Complications impacting prognosis

• Mobility disability: progressive distal muscle wasting and contractures can lead to walking difficulty and eventual wheelchair dependence. (arora2021primrosesyndromea pages 6-8)
• Tumors: testicular tumors have been reported in adult males; tumor-related mortality occurred in the cohort (“the two males with PS who developed testicular tumors have died because of their tumors”). (melis2020primrosesyndromecharacterization pages 8-10)

11.4 Quality of life proxy outcomes from interventions

A 2024 case report indicates substantial sustained improvement in severe neurobehavioral symptoms with sertraline (resolution within 2 weeks; persisted >2 years), enabling better participation in therapy and schooling (functional benefit). (moon2024resolutionofsevere pages 2-2)

12. Treatment

12.1 Current standard of care (supportive)

No disorder-specific disease-modifying treatment is established; management is multidisciplinary supportive care, including early intervention (speech/OT/PT), educational planning, behavioral assessment, seizure monitoring and standard ASM use when indicated, orthopedics/rehabilitation for musculoskeletal complications, audiology monitoring and hearing aids, and endocrine surveillance/management (glucose/HbA1c beginning ~age 7; thyroid monitoring). (arora2021primrosesyndrome pages 8-10, arora2021primrosesyndromea pages 10-13)

12.2 Real-world implementations (2024)

• SSRI for neurobehavioral symptoms: A single-case report described resolution of severe aggression/irritability/mood lability with sertraline (started 25 mg daily; improvement in 2 weeks; later increased to 50 mg; sustained benefit >2 years). (moon2024resolutionofsevere pages 2-2, moon2024resolutionofsevere pages 1-2)
• Cochlear implantation: A child underwent unilateral cochlear implantation (Nucleus CI422) after unsuccessful hearing-aid trial, with 3-month post-op PTA ~40 dB and emerging 1–3 word sentences. (tugci2024cochlearimplantationin pages 2-4)

12.3 MAXO suggestions (examples)

• Hearing evaluation; hearing aid therapy; cochlear implantation; speech therapy; occupational therapy; physical therapy; behavioral therapy; SSRI pharmacotherapy; endocrine monitoring; diabetes pharmacotherapy.

(These MAXO suggestions are based on interventions described in the clinical evidence and are provided for knowledge base mapping.) (arora2021primrosesyndrome pages 8-10, tugci2024cochlearimplantationin pages 2-4, moon2024resolutionofsevere pages 2-2)

12.4 Clinical trials

A clinical trials search returned no clearly Primrose syndrome/ZBTB20-targeted interventional trials in the retrieved set; listed trials were unrelated false positives (e.g., “primrose oil”).

13. Prevention

Primrose syndrome is genetic; therefore prevention is primarily reproductive/genetic: - Genetic counseling with recurrence risk assessment. - Prenatal and preimplantation genetic testing are possible once the familial ZBTB20 pathogenic variant is known. (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)

Secondary/tertiary prevention focuses on anticipatory surveillance: audiology, glucose/HbA1c, thyroid function, musculoskeletal monitoring, and in adult males consideration of testicular tumor vigilance (though no standardized TGCT surveillance protocol exists). (arora2021primrosesyndromea pages 10-13, melis2020primrosesyndromecharacterization pages 8-10)

14. Other Species / Natural Disease

No naturally occurring veterinary/other-species disease equivalent was identified in the retrieved evidence; however, multiple mouse experimental models of Zbtb20 perturbation exist that inform neurodevelopmental mechanisms. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)

15. Model Organisms

Experimental evidence relevant to Primrose syndrome mechanisms includes: - Mouse genetic perturbation / transgenic expression: Zbtb20 deletion or ectopic expression affects hippocampal development and cortical lamination; CA1 pyramidal neuron maturation is sensitive to Zbtb20 downregulation. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2) - In vitro/cell-based functional assays: mutant ZBTB20 proteins show impaired chromatin/DNA binding and interference with wild-type binding, supporting dominant-negative effects. (stellacci2018clinicalandfunctional pages 13-16)

Recent developments and “latest research” emphasis (2023–2024)

The most clinically actionable 2023–2024 developments in the retrieved literature are: 1. Medication response report: sertraline leading to sustained resolution of severe neurobehavioral symptoms (2024). (moon2024resolutionofsevere pages 2-2) 2. Device-based intervention: first reported cochlear implantation experience in Primrose syndrome with short-term audiologic/language gains (2024). (tugci2024cochlearimplantationin pages 2-4) 3. Expanded early-life recognition and prenatal diagnosis: fetal exome sequencing with prenatal imaging features and novel truncating variant (2023), and additional infant/toddler cases with early features before classic adolescence-onset signs (2024). (long2023aninfantwith pages 1-2, sogukpınar2024anovelzbtb20 pages 1-2) 4. Variant spectrum and ACMG-coded interpretation: first Chinese case with de novo p.F643I, classified likely pathogenic with explicit ACMG evidence codes (2024). (li2024noveldenovo pages 5-7)

High-yield summary table (identifiers, phenotypes, biomarkers, and 2023–2024 cases)

Table: This table condenses high-yield identifiers, phenotype frequencies, biochemical markers, and recent 2023-2024 case reports for Primrose syndrome. It is designed as a quick-reference artifact for knowledge base curation and evidence-backed clinical summary writing.

Notes on evidence gaps

• ICD/MeSH identifiers were not present in the retrieved full-text excerpts.
• Many “statistics” beyond the 42-patient cohort are limited by rarity and publication bias (case reports).
• No disease-modifying therapy trials were identified in the clinical trial query results.

Key source URLs (publication dates)

• Melis et al., Clinical Genetics (Apr 2020): https://doi.org/10.1111/cge.13749 (melis2020primrosesyndromecharacterization pages 2-4)
• Juven et al., Eur J Hum Genet (Feb 2020): https://doi.org/10.1038/s41431-020-0582-3 (juven2020primrosesyndromea pages 1-2)
• Arora et al., GeneReviews-style chapter (2021): (URL not provided in retrieved excerpt) (arora2021primrosesyndrome pages 10-13)
• Long et al., Cureus (Oct 2023): https://doi.org/10.7759/cureus.46546 (long2023aninfantwith pages 1-2)
• Głowska-Ciemny et al., Cancers (Aug 2023): https://doi.org/10.3390/cancers15174302 (głowskaciemny2023roleofalphafetoprotein pages 3-4)
• Moon et al., Am J Med Genet A (Mar 2024): https://doi.org/10.1002/ajmg.a.63610 (moon2024resolutionofsevere pages 1-2)
• Soğukpınar et al., Molecular Syndromology (Mar 2024): https://doi.org/10.1159/000537952 (sogukpınar2024anovelzbtb20 pages 1-2)
• Tuğci et al., Turkish Archives of Otorhinolaryngology (Dec 2024): https://doi.org/10.4274/tao.2023.2023-4-5 (tugci2024cochlearimplantationin pages 2-4)
• Li et al., Molecular Genetics & Genomic Medicine (Dec 2024): https://doi.org/10.1002/mgg3.2304 (li2024noveldenovo pages 1-2)

References

1. (OpenTargets Search: Primrose syndrome-ZBTB20): Open Targets Query (Primrose syndrome-ZBTB20, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (melis2020primrosesyndromecharacterization pages 2-4): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.

3. (arora2021primrosesyndrome pages 1-3): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

4. (melis2020primrosesyndromecharacterization pages 1-2): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.

5. (arora2021primrosesyndrome pages 10-13): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

6. (sogukpınar2024anovelzbtb20 pages 1-2): Merve Soğukpınar, Beren Karaosmanoğlu, Gülen Eda Utine, Koray Boduroğlu, and Pelin Özlem Şimşek-Kiper. A novel zbtb20 variant in a patient with primrose syndrome: a rare clinical entity with distinctive features. Molecular Syndromology, 15:347-354, Mar 2024. URL: https://doi.org/10.1159/000537952, doi:10.1159/000537952. This article has 0 citations and is from a peer-reviewed journal.

7. (li2024noveldenovo pages 1-2): Jiayi Li, Chuan Zhang, Xinyuan Tian, Bingbo Zhou, Xue Chen, Yupei Wang, Shengju Hao, Ling Hui, and Zhaoyan Meng. Novel de novo mutation in zbtb20 in a chinese primrose syndrome family and a review of the literature. Molecular Genetics & Genomic Medicine, Dec 2024. URL: https://doi.org/10.1002/mgg3.2304, doi:10.1002/mgg3.2304. This article has 1 citations and is from a peer-reviewed journal.

8. (tugci2024cochlearimplantationin pages 2-4): Burak Anıl Tuğci, Alper Gezdirici, Can Berk Aşaroğlu, Ercan Atasoy, İbrahim Sayın, and Zahide Mine Yazıcı. Cochlear implantation in primrose syndrome with a novel zbtb20 gene variant. Turkish Archives of Otorhinolaryngology, 61:192-200, Dec 2024. URL: https://doi.org/10.4274/tao.2023.2023-4-5, doi:10.4274/tao.2023.2023-4-5. This article has 0 citations.

9. (long2023aninfantwith pages 1-2): Calista Long, Barry DeRose, Anthony B Lal, and Elizabeth Imboden. An infant with primrose syndrome: a case report. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.46546, doi:10.7759/cureus.46546. This article has 2 citations.

10. (melis2020primrosesyndromecharacterization pages 4-7): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.

11. (arora2021primrosesyndromea pages 6-8): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

12. (melis2020primrosesyndromecharacterization pages 8-10): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.

13. (juven2020primrosesyndromea pages 1-2): Aurélien Juven, Sophie Nambot, Amélie Piton, Nolwenn Jean-Marçais, Alice Masurel, Patrick Callier, Nathalie Marle, Anne-Laure Mosca-Boidron, Paul Kuentz, Christophe Philippe, Martin Chevarin, Yannis Duffourd, Elodie Gautier, Arnold Munnich, Marlène Rio, Sophie Rondeau, Salima El Chehadeh, Élise Schaefer, Bénédicte Gérard, Sonia Bouquillon, Catherine Vincent Delorme, Christine Francannet, Fanny Laffargue, Laetitia Gouas, Bertrand Isidor, Marie Vincent, Sophie Blesson, Fabienne Giuliano, Olivier Pichon, Cédric Le Caignec, Hubert Journel, Laurence Perrin-Sabourin, Jennifer Fabre-Teste, Dominique Martin, Gaelle Vieville, Klaus Dieterich, Didier Lacombe, Anne-Sophie Denommé-Pichon, Christel Thauvin-Robinet, and Laurence Faivre. Primrose syndrome: a phenotypic comparison of patients with a zbtb20 missense variant versus a 3q13.31 microdeletion including zbtb20. European Journal of Human Genetics, 28:1044-1055, Feb 2020. URL: https://doi.org/10.1038/s41431-020-0582-3, doi:10.1038/s41431-020-0582-3. This article has 21 citations and is from a domain leading peer-reviewed journal.

14. (arora2021primrosesyndrome pages 6-8): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

15. (li2024noveldenovo pages 5-7): Jiayi Li, Chuan Zhang, Xinyuan Tian, Bingbo Zhou, Xue Chen, Yupei Wang, Shengju Hao, Ling Hui, and Zhaoyan Meng. Novel de novo mutation in zbtb20 in a chinese primrose syndrome family and a review of the literature. Molecular Genetics & Genomic Medicine, Dec 2024. URL: https://doi.org/10.1002/mgg3.2304, doi:10.1002/mgg3.2304. This article has 1 citations and is from a peer-reviewed journal.

16. (arora2021primrosesyndromea pages 10-13): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

17. (moon2024resolutionofsevere pages 1-2): Young Min Moon, Sa Eun Park, Constance Smith‐Hicks, and Aaron Hauptman. Resolution of severe neurobehavioral difficulties in an individual with primrose syndrome with sertraline. American Journal of Medical Genetics Part A, Mar 2024. URL: https://doi.org/10.1002/ajmg.a.63610, doi:10.1002/ajmg.a.63610. This article has 1 citations.

18. (stellacci2018clinicalandfunctional pages 13-16): Emilia Stellacci, Katharina Steindl, Pascal Joset, Laura Mercurio, Massimiliano Anselmi, Serena Cecchetti, Laura Gogoll, Markus Zweier, Annette Hackenberg, Gianfranco Bocchinfuso, Lorenzo Stella, Marco Tartaglia, and Anita Rauch. Clinical and functional characterization of two novel zbtb20 mutations causing primrose syndrome. Human Mutation, 39:959-964, Jul 2018. URL: https://doi.org/10.1002/humu.23546, doi:10.1002/humu.23546. This article has 21 citations and is from a domain leading peer-reviewed journal.

19. (long2023aninfantwith pages 6-7): Calista Long, Barry DeRose, Anthony B Lal, and Elizabeth Imboden. An infant with primrose syndrome: a case report. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.46546, doi:10.7759/cureus.46546. This article has 2 citations.

20. (głowskaciemny2023roleofalphafetoprotein pages 3-4): Joanna Głowska-Ciemny, Marcin Szymanski, Agata Kuszerska, Rafał Rzepka, Constantin S. von Kaisenberg, and Rafał Kocyłowski. Role of alpha-fetoprotein (afp) in diagnosing childhood cancers and genetic-related chronic diseases. Cancers, 15:4302, Aug 2023. URL: https://doi.org/10.3390/cancers15174302, doi:10.3390/cancers15174302. This article has 34 citations.

21. (głowskaciemny2023roleofalphafetoprotein pages 4-6): Joanna Głowska-Ciemny, Marcin Szymanski, Agata Kuszerska, Rafał Rzepka, Constantin S. von Kaisenberg, and Rafał Kocyłowski. Role of alpha-fetoprotein (afp) in diagnosing childhood cancers and genetic-related chronic diseases. Cancers, 15:4302, Aug 2023. URL: https://doi.org/10.3390/cancers15174302, doi:10.3390/cancers15174302. This article has 34 citations.

22. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2): Kelly A. Jones, Yue Luo, Lynn Dukes-Rimsky, Deepak P. Srivastava, Richa Koul-Tewari, Theron A. Russell, Lauren P. Shapiro, Anand K. Srivastava, and Peter Penzes. Neurodevelopmental disorder-associated zbtb20 gene variants affect dendritic and synaptic structure. PLoS ONE, 13:e0203760, Oct 2018. URL: https://doi.org/10.1371/journal.pone.0203760, doi:10.1371/journal.pone.0203760. This article has 38 citations and is from a peer-reviewed journal.

23. (melis2020primrosesyndromecharacterization pages 10-11): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.

24. (moon2024resolutionofsevere pages 2-2): Young Min Moon, Sa Eun Park, Constance Smith‐Hicks, and Aaron Hauptman. Resolution of severe neurobehavioral difficulties in an individual with primrose syndrome with sertraline. American Journal of Medical Genetics Part A, Mar 2024. URL: https://doi.org/10.1002/ajmg.a.63610, doi:10.1002/ajmg.a.63610. This article has 1 citations.

25. (arora2021primrosesyndrome pages 8-10): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01